Skip to main content

ValiRx news roundup: September 2023

5 Oct 2023


This roundup features our news, updates, and highlights from September. This month, our subsidiary company Inaphaea BioLabs’ much anticipated launch event took place, and we’re pleased to say it was a resounding success. 

To discuss any of our updates, please contact ValiRx CEO Dr Suzy Dilly who will be happy to help.

Inaphaea BioLabs launch event

On 26 September, we hosted an official launch event for Inaphaea BioLabs at MediCity Nottingham, supported by BioNow. 

We’d like to take the opportunity to thank everyone who attended the event – from our neighbours and industry friends to collaborators and partners - to network and share insights and ideas. A special thanks goes to the keynote speakers, company showcase speakers, and to BioNow for helping us make this event possible.

The afternoon started with coffee and lunch, followed by a warm welcome from BioNow’s Stella James and Inaphaea’s Head of Strategic Development Dr Andrew Carnegie. 

Our company showcases came next, with fascinating talks from HistologiX's Head of Client Management Dr Peter De'Ath, Inspiralis Ltd's Managing Director Natassja Bush, Venomtech Ltd's Founder & CSO Steve Trim and Agility Life Sciences' Founder and CEO Professor Claire Thompson.

Guests enjoyed a tour of our laboratory and an exclusive look at our brand-new set up, which was closely followed by keynote speeches from our team. Inaphaea’s Scientific Consultant Dr Gareth Griffiths spoke about patient-derived cells in drug discovery and Chief Scientific Officer Cathy Tralau-Stewart discussed drug discovery attrition and the role of human-based cells in drug discovery.

We’re looking forward to sharing photos and videos from the event – stay tuned for more!

Meet Gerry Desler

Earlier this month, we sat down with our Finance Director Gerry Desler to learn more about his role and how he works with ValiRx board to ensure the smooth running of the company. 

With a wealth of financial and AIM experience, Gerry has been with ValiRx from the very beginning and with his impressive length of service, brings a strong knowledge base that informs the company’s decision-making. 

Read more here. 

Q3 operational update

On 28 September, we released our quarterly review of activities across the ValiRx group. This includes a round-up of Inaphaea’s progress this quarter, the Barcelona University evaluation, further evaluation projects, and an update on our preclinical stage assets including CLX001, VAL301, and BC201.

Further details are available here. 

ValiRx CEO Dr Suzy Dilly and Non-executive Chairman Dr Kevin Cox also hosted a Q&A session to provide further background on the update. 

Watch the recording of the Q&A here. 

ValiRx CSO featured in Drug Discovery World 

Our CSO Dr Cathy Tralau-Stewart has featured in the latest issue of Drug Discovery World, commenting in the market report on the innovation taking place across UK drug discovery. 

Cathy speaks about academic translational sciences, and its approach to translating scientific discoveries and research into practical applications to benefit patients.

Read the digital version of the magazine here.

Inaphaea lab launch